NCT00160641 - A Study of the Safety and Effectiveness of Liquid Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis | Biotech Hunter

Enrollment

567

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions

Rheumatoid Arthritis

Interventions

BIOLOGICAL

Certolizumab Pegol

"Strength and Form: 1 ml of Liquid product containing 200 mg of Certolizumab Pegol (CZP) given as a subcutaneous injection.~Dosage and Frequency: 400 mg every two weeks for at least 6 months, then 200 mg every two weeks.~Duration: Until end of study."

Trial Locations (67)

Unknown

172, Palm Desert

185, Pasadena

170, Santa Maria

194, Whittier

176, Naples

186, Palm Harbor

188, Kansas City

182, St Louis

178, Stratford

192, Amarillo

173, Austin

175, San Antonio

303, Pleven

302, Sofia

500, Rijeka

600, Brno

603, Hlučín

605, Prague

606, Prague

604, Sokolov

602, Uherské Hradiště

607, Zlín

700, Tallinn

802, Afula

805, Ashkelon

807, Haifa

804, Jerusalem

801, Ramat Gan

806, Ẕerifin

901, Daugavpils

900, Riga

103, Alytus

100, Kaunas

102, Klaipėda

101, Šiauliai

124, Bialystok

120, Elblag

123, Krakow

125, Lublin

121, Sopot

122, Torun

150, Moscow

151, Moscow

156, Moscow

159, Moscow

152, Saint Petersburg

154, Saint Petersburg

155, Saint Petersburg

158, Saint Petersburg

153, Yaroslavl

132, Belgrade

133, Belgrade

131, Niška Banja

141, Košice

143, Košice

140, Piešťany

142, Piešťany

162, Dnipro

161, Donetsk

168, Donetsk

165, Ivano-Frankivsk

163, Kiev

164, Kiev

167, Kiev

169, Kiev

160, Simferopol

166, Zaporizhzhya